NCT04144608View on ClinicalTrials.gov

Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

July 30, 2023

Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DRUG

Toripalimab

Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1

Trial Locations (1)

410013

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors
lead

Yongchang Zhang

OTHER

NCT04144608 - Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC | Biotech Hunter | Biotech Hunter